Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Oral Medications Articles

Type 2: Oramed Sends Oral Insulin Test Request to FDA
ACP Guidelines Say Metformin Is the Best Starter Drug for Type 2s
FDA Gives Long-Awaited Nod to Amylin’s Bydureon
Oral Medications Archives
Browse the Oral Medications Archives
Subscribe to the Medications RSS Feed

Oral Medications Article Archives

January 2013

Type 2: Oramed Sends Oral Insulin Test Request to FDA
news
Type 2: Oramed Sends Oral Insulin Test Request to FDA

Israel-based Oramed announced that it has sent an application to the Food and Drug Administration for permission to enter Phase 2 trials of its oral insulin product. The company has been working on developing a means of delivering insulin orally, which would allow people with diabetes to avoid having to inject themselves with the hormone.

comments 2 comments - Posted Jan 16, 2013

March 2012

ACP Guidelines Say Metformin Is the Best Starter Drug for Type 2s
news
ACP Guidelines Say Metformin Is the Best Starter Drug for Type 2s

The latest clinical guidelines for treating type 2 diabetes from the American College of Physicians (ACP) indicate that when diet, exercise, and weight loss fail to control blood sugar levels in early type 2 patients, physicians should prescribe metformin as the first drug therapy.

comments 2 comments - Posted Mar 1, 2012

February 2012

FDA Gives Long-Awaited Nod to Amylin’s Bydureon
news
FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.

comments 2 comments - Posted Feb 3, 2012

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.